NCT03480750 · OUTCOME

Progression-free Survival

Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer · Source last updated 2020-11-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: months
Interval / dispersion: 95% Confidence Interval
Time frame: 36 months

What was measured

Time is calculated from the diagnosis to the last follow-up date if no disease progression , or the date of disease progression after the last treatment cycle of the study drugs

Analysis population: According the protocol for this secondary outcome, data collected from participants receiving different dose levels were intended to be combined and analyzed as a single group.

Groups in this outcome

Trientine With Chemotherapy

trientine dihydrochloride PO daily \[through dose level 1 (300mg/day) to level 6 (1800mg/day)\] plus pegylated liposomal doxorubicin IV D1 plus carboplatin IV D1 trientine dihydrochloride: trientine dihydrochloride 300MG/CAPSUE PO daily \[through dose level 1 (300mg/day) to level 6 (1800mg/day)\] pegylated liposomal doxorubicin: pegylated liposomal doxorubicin 40mg/m2 IV D1 carboplatin: carboplatin AUC 4 IV D1

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Trientine With Chemotherapy	16

Reported measurements

Source class 1

Values in months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Trientine With Chemotherapy	4.6	Not reported	0	11.3	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
0
upper Limit
11.3
value
4.6

denoms

counts
group Id
OG000
value
16
units
Participants

description

Time is calculated from the diagnosis to the last follow-up date if no disease progression , or the date of disease progression after the last treatment cycle of the study drugs

dispersion Type

95% Confidence Interval

groups

description
trientine dihydrochloride PO daily \[through dose level 1 (300mg/day) to level 6 (1800mg/day)\] plus pegylated liposomal doxorubicin IV D1 plus carboplatin IV D1 trientine dihydrochloride: trientine dihydrochloride 300MG/CAPSUE PO daily \[through dose level 1 (300mg/day) to level 6 (1800mg/day)\] pegylated liposomal doxorubicin: pegylated liposomal doxorubicin 40mg/m2 IV D1 carboplatin: carboplatin AUC 4 IV D1
id
OG000
title
Trientine With Chemotherapy

param Type

MEDIAN

population Description

According the protocol for this secondary outcome, data collected from participants receiving different dose levels were intended to be combined and analyzed as a single group.

reporting Status

POSTED

time Frame

36 months

title

Progression-free Survival

type

SECONDARY

unit Of Measure

months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice